Track C4 Therapeutics's total current liabilities ($27M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), CCCC shows a total current liabilities of $27M. That compares with $41M in the prior-year period — down 33.2% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CCCC's total current liabilities is now $27M (was $41M) — a 33.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether C4 Therapeutics is outperforming or lagging.
Tracking CCCC's total current liabilities over time shows whether C4 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $27M That compares with $41M in the prior-year period — down 33.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total current liabilities page, Stockcircle has C4 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $27M) with ownership activity and broader fundamentals.
C4 Therapeutics's total current liabilities is $27M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.